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Complement factor H binding of 
monomeric C-reactive protein 
downregulates proinflammatory 
activity and is impaired with at risk 
polymorphic CFH variants
Blanca Molins1, Pablo Fuentes-Prior2,3, Alfredo Adán1, Rosa Antón2, Juan I. Arostegui4, 
Jordi Yagüe4 & Andrew D. Dick5,6
Inflammation and immune-mediated processes are pivotal to the pathogenic progression of age-related 
macular degeneration (AMD). Although plasma levels of C-reactive protein (CRP) have been shown to 
be associated with an increased risk for AMD, the pathophysiological importance of the prototypical 
acute-phase reactant in the etiology of the disease is unknown, and data regarding the exact role of 
CRP in ocular inflammation are limited. In this study, we provide mechanistic insight into how CRP 
contributes to the development of AMD. In particular, we show that monomeric CRP (mCRP) but not the 
pentameric form (pCRP) upregulates IL-8 and CCL2 levels in retinal pigment epithelial cells. Further, we 
show that complement factor H (FH) binds mCRP to dampen its proinflammatory activity. FH from AMD 
patients carrying the “risk” His402 polymorphism displays impaired binding to mCRP, and therefore 
proinflammatory effects of mCRP remain unrestrained.
Age-related macular degeneration (AMD) is the primary cause of irreversible vision loss among the ageing pop-
ulation worldwide. The disease affects up to 1.75 million individuals alone in the United States, and this number 
could increase up to 3 million by 20201–3. Worldwide, the projected number of people with AMD in 2020 is 
196 million (95% CrI 140–261), which increases to 288 million in 2040 (205–399)4. Local inflammation and 
immune-mediated processes play a central role in AMD pathogenesis5. Proteomic and histochemical analysis of 
ocular drusen, the hallmark deposits of AMD, have shown that these deposits contain inflammatory proteins and 
complement components that mediate local inflammation6,7. Furthermore, polymorphisms in a gene essential 
for the regulation of complement activation, CFH, are an important risk factor for developing AMD8,9. These and 
other findings have stimulated research to understand the role of immune responses in the development of the 
disease.
C-reactive protein (CRP) is the prototypical acute-phase reactant and an active regulator of the innate 
immune system. It is considered to be a serum biomarker for chronic inflammation, heart disease and, more 
recently, AMD10–12. CRP has been identified in ocular drusen and other subretinal pigmented epithelium depos-
its13,14, as well as in the choroid, but little is known about its function in the context of AMD. Among the multiple 
functions ascribed to CRP are activation of the classical complement pathway and inactivation of the alternative 
pathway15. In addition, in the context of atherosclerosis, CRP upregulates the expression of adhesion molecules, 
and increases cytokine release from endothelial cells, neutrophils and macrophages16–18.
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In plasma, CRP exists as a cyclic non-covalent pentamer of 125-kDa composed of five identical Ca2+-stabilized 
subunits, which are placed in the corners of a regular pentagon19. (See Supplemental Figure 1A for a representa-
tion of the three-dimensional (3D) crystal structure of pentameric CRP (pCRP); notice that a phosphocholine 
molecule is bound to each of the five independent binding sites)20. However, oxidative stress, low pH, and bio-
active lipids from activated or damaged cells can dissociate pCRP into its 23-kDa subunits21–24. This poorly sol-
uble, tissue-based monomeric form, mCRP, possesses distinct biological functions compared to pCRP23. For 
instance, mCRP induces proinflammatory responses in neutrophils and endothelial cells, in contrast to the 
anti-inflammatory functions of pCRP25–27. Further, data shows that, unlike pCRP, mCRP elicits a prothrombotic 
and proinflammatory response in platelets and monocytes28–30.
Complement factor H (FH) is a major inhibitor of the alternate complement pathway. FH regulates comple-
ment activation in plasma, host cells and tissue, in particular at sites of tissue inflammation, following injury or 
during degeneration31. The protein is essentially comprised of 20 tandem Sushi domains, also known as short 
consensus repeat (SCR) or complement control protein (CCP) modules. A common polymorphism in the CFH 
gene (c.1277T> C, p.Tyr402His) is highly associated with the development of AMD; the CFH p.Tyr402His var-
iant (in following termed CFHH402) increases the risk for AMD ∼ 2–4-fold for heterozygous and 5–7-fold for 
homozygous individuals32–34. The exchanged residue is located in FH domain SCR7, which mediates cell surface 
binding through interactions with heparan sulfate chains35,36. FH is in addition known to bind CRP, but there 
is an ongoing controversy regarding the relevance of the monomeric and pentameric forms in this regard. For 
instance, two separate binding sites for pCRP were located on domains SCR4–6 and SCR16–20, respectively36. On 
the other hand, FH showed strong binding to denatured, monomeric CRP, rather than to the native multimeric 
form37,38. Of particular note, the non-risk associated variant FHY402 binds CRP more strongly than the H402 risk 
variant39–41. As a consequence, individuals who are homozygous for the latter show 2.5-fold higher CRP levels in 
the retinal pigment epithelium (RPE)–choroid layer compared with those homozygous for the non-risk variant40.
Although mCRP has been localized within retinal tissues, the contribution to immune responses and to AMD 
onset and progression has not been clarified. The data supports our hypothesis that mCRP contributes to the 
development of AMD through direct proinflammatory effects on retinal pigment epithelial cells, and that this 
proinflammatory activity is unchecked in subjects with the “at risk” Tyr402His polymorphism in CFH, due to an 
impaired interaction with mCRP.
Results
Monomeric but not pentameric CRP induces IL8 and CCL2 gene expression and protein secretion. 
To determine the effect of CRP isoforms on the expression of inflammatory mediators, ARPE-19 cells were 
exposed for 24 h to different concentrations of either mCRP or pCRP. mRNA levels of IL8 and CCL2 were deter-
mined by quantitative RT-PCR, and protein concentrations of both cytokines in the supernatants were quantified 
by ELISA. As observed in Fig. 1A, mCRP significantly and dose-dependently increased IL8 mRNA expression 
(P < 0.05), reaching statistical significance at a concentration of 2 μg/mL. By contrast, pCRP was unable to induce 
IL-8 expression at any concentration tested. Consistent with the stimulation of IL8 gene expression, mCRP signif-
icantly and dose-dependently augmented the secretion of IL-8 (Fig. 1B). By contrast, pCRP was unable to induce 
IL-8 secretion at any concentration tested. Similar to the effect on IL-8, only mCRP significantly increased CCL2 
mRNA expression levels in a dose-dependent manner, reaching significance at 5 μg/mL (Fig. 1C). Concentrations 
of the secreted cytokine were also significantly higher in cultures treated with the monomeric CRP form, as com-
pared to pCRP (Fig. 1D). To rule out the possibility that pCRP at equal molar concentrations as mCRP (and thus 
at a five-fold higher concentration of binding sites) could exert a similar response as the monomeric form, we 
determined mRNA and secreted protein levels of IL-8 from ARPE-19 cells in response to increasing concentra-
tions of m/pCRP (from 0 to 2.5 mM). As shown in Supplementary Figure S2, the monomeric form significantly 
increased IL8 gene expression and protein secretion at concentrations above 0.25 mM while pCRP was unable to 
stimulate IL-8 secretion at any concentration tested.
Fcγ receptors have been postulated to play a role downstream of CRP binding25–26. We addressed this issue 
by blocking CD16 (Fcγ -RIII) or CD32 (Fcγ -RIIa) receptors with specific mAbs. Blockade of CD32 did not pre-
vent mCRP-induced upregulation of IL-8 and CCL2 in ARPE-19 cells (Supplementary Figure S3). By contrast, 
blockade of CD16 prevented CCL2, but not IL-8 upregulation. To further investigate whether MAPK pathways 
were involved in mCRP-induced upregulation of cytokine expression, ARPE-19 cells were treated with p38 
inhibitor SB-203580, MEK inhibitor U0126 or JNK inhibitor SP-600125 for 30 min prior to mCRP treatment. 
mCRP-induced secretion levels of IL-8 and CCL2 were partially reduced by SB203580 and completely reverted 
by the JNK inhibitor. However, the MEK inhibitor did not significantly influence secretion of any of the cytokines 
(Supplementary Figure S4).
Conditioned medium from mCRP-treated ARPE-19 cells stimulates PBMC migration. Since 
mCRP induced secretion of proinflammatory and chemotactic mediators from ARPE-19 cells, we wished to 
evaluate the functional consequences of this upregulation. For this purpose, we performed assays to evaluate 
whether the conditioned medium of CRP-treated ARPE-19 cells had a chemotactic effect on healthy PBMC. We 
observed that none of the CRP isoforms per se had chemotactic activity on PBMC, as the number of migrated 
cells did not change when mCRP or pCRP were added to RPMI1640 medium (Fig. 2). Conditioned medium 
from non-stimulated ARPE-19 cells did not show chemotactic properties, as the number of cells migrated after 
3 h stimulation was similar to the effect produced by RPMI1640 medium alone. On the contrary, conditioned 
medium from mCRP-stimulated but not from pCRP-stimulated cells significantly increased PBMC migration 
(P < 0.05). These observations suggest that mCRP confers a proinflammatory phenotype to ARPE-19 cells, which 
further induces PBMC migration.
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Proinflammatory cytokines do not induce CRP expression in ARPE-19 cells. To elucidate whether 
CRP is expressed locally by RPE cells, ARPE-19 cells were cultured in the presence of different proinflamma-
tory cytokines for 24 to 48 h, and CRP mRNA was analyzed by RT-PCR. No evidence of CRP gene transcrip-
tion was detected in ARPE-19 cells after these incubation times. When transcriptional data was analyzed using 
low-stringency PCR baseline levels, small quantities of CRP mRNA were detected in ARPE–19 cells, especially 
upon stimulation with IL-17 (Supplementary Figure S5). However, these levels are almost indistinguishable from 
Figure 1. Monomeric, but not pentameric CRP isoforms stimulate IL-8 and CCL2 expression. ARPE-19 
cells were stimulated with the indicated concentrations of CRP isoforms for 24 h. Gene expression levels of IL8 
(A) and CCL2 (C) as well as secreted concentrations of these cytokines (B,D) were determined by real-time 
PCR and ELISA, respectively (n = 7). Statistical analysis was performed by ANOVA (*P < 0.05).
Figure 2. Cytokines secreted by mCRP-treated ARPE-19 cells potently stimulate PBMC migration. 
Chemotaxis assay was performed using Transwell chambers. PBMC from healthy donors were seeded into 
the upper wells, while the lower chambers contained either RPMI medium supplemented with 10 μg/mL 
mCRP or pCRP, or conditioned medium from ARPE-19 cells stimulated with the indicated concentrations of 
CRP isoforms, and diluted 1:1 with RPMI. The results of these experiments are expressed as fold-change vs. 
control ± SEM after 3 h incubation (n = 4). Statistical analysis was performed by ANOVA (*P < 0.05).
www.nature.com/scientificreports/
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nonspecific background amplification. Similarly, CRP levels in the supernatants of ARPE-19 treated cells were 
below the detection limit (0.4 ng/mL) under all tested conditions.
FH prevents the proinflammatory effects of mCRP on ARPE-19 cells. Because FH has been 
reported to bind CRP, we next evaluated whether FH could prevent the proinflammatory effect of mCRP. For this 
purpose, ARPE-19 cells were exposed to purified commercial FH 30 min before CRP treatment. Indeed, addi-
tion of the complement regulator reduced mCRP-induced upregulation of IL8 gene expression, although it was 
not able to completely prevent an increase in IL8 mRNA levels at the concentrations tested (Fig. 3A). In striking 
contrast, neither FH alone nor FH added in the presence of pCRP had any effect on IL-8 secretion by ARPE-19 
cells. Further, addition of FH prevented mCRP-induced IL-8 secretion in a dose-dependent manner (Fig. 3B). In 
a similar manner, pre-incubation with FH dose-dependently prevented an increase in CCL2 mRNA expression 
upon mCRP stimulation (Fig. 3C) as well as mCRP-induced CCL2 secretion (Fig. 3D). As observed for IL-8, 
neither FH alone nor FH in the presence of pCRP had any impact on CCL2 secretion.
To further elucidate whether FH could also reverse the enhanced PBMC migration induced by conditioned 
medium from mCRP-treated ARPE-19 cells, chemotaxis experiments were performed essentially as described 
above. Medium from ARPE-19 cells treated with FH plus mCRP (5 and 10 μg/mL) induced PBMC migration to a 
similar extent to that from untreated ARPE-19 cells, and significantly lower than conditioned medium from cells 
treated with mCRP alone (P < 0.05, Fig. 4).
FH binds to monomeric, but not to pentameric CRP. We next evaluated the impact of varia-
tions at position 402 of FH on the interaction with CRP isoforms. For this purpose, binding of immobilized 
mCRP or pCRP to FH variants was assessed by ELISA using sera from genotyped AMD patients. FH bound 
dose-dependently to immobilized, monomeric CRP but not to the pentameric form (Fig. 5). Of particular 
note, the non-risk associated variant FHY402 bound significantly tighter to mCRP than the risk variant FHH402 
(P < 0.05).
“Non-risk” but not “at risk” FH prevents the proinflammatory effects of mCRP on ARPE-19 
cells. To test whether the impaired FH-mCRP interaction in individuals carrying the FHH402 risk variant could 
affect the ability of FH to prevent the mCRP-induced pro-inflammatory phenotype, ARPE-19 cells were treated 
Figure 3. FH counteracts mCRP-induced upregulation of IL-8 and CCL2 in ARPE-19 cells. Cells were 
stimulated with FH before adding CRP isoforms for 24 h. mRNA expression levels of IL8 (A) and CCL2 (C) 
were determined using real-time PCR (A, C), while concentrations of secreted proteins (B, D) were measured 
by ELISA (n = 5). Statistical analysis was performed by ANOVA (*P < 0.05 vs. control, #P < 0.05 vs. mCRP plus 
FH).
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with FH purified from sera of genotyped AMD patients prior to incubation with mCRP. (Because two different 
commercial antibodies against human FH showed strong cross-reactivity with complement factor C3, we rou-
tinely verified authenticity of purified FH by mass spectrometry analysis of tryptic digests; see Supplementary 
Figure S6 for this quality control). Interestingly, the non-risk associated variant of FH showed a significantly 
higher ability to prevent mCRP-induced IL-8 and CCL2 up-regulation than the FHH402 isoform (Fig. 6).
Finally, to test whether the CFHH402 risk variant could affect the systemic levels of IL-8, serum concentra-
tions of IL-8 and CRP were determined in genotyped AMD patients and sex- and age-matched controls. AMD 
patients carrying the risk variant had significantly higher levels of both IL-8 (P = 0.03) and hsCRP (P = 0.002) 
than healthy subjects carrying the non-risk variant (Fig. 7). Moreover, the levels of CRP and IL-8 in serum were 
positively correlated in all subjects (Spearman’s rho r = 0.317, P < 0.01) and in particular in the subgroup of AMD 
patients homozygous for the risk CFH variant (r = 0.545, P < 0.01). Finally, it is noteworthy that healthy subjects 
carrying the non-risk variant had significantly lower levels of hsCRP than the other three groups.
Discussion
Inflammation and immune-mediated processes are crucial for the pathogenesis of AMD and this study strength-
ens observations that plasma levels of CRP are associated with an increased risk for AMD10,12,42. In the current 
work, we provide mechanistic insight on how CRP contributes to the development of AMD. First, we show that 
monomeric CRP but not the pentameric form upregulates the proinflammatory cytokines, IL-8 and CCL2, in 
retinal pigment epithelial cells. Further, we demonstrate that the regulator of complement responses, FH, binds 
mCRP to attenuate its proinflammatory activity. Finally, and corroborating cell culture findings, FH from AMD 
patients carrying the H402 risk variant also displayed impaired binding to mCRP, potentially leaving the proin-
flammatory effects of mCRP unchecked.
IL-8 and CCL2 are critically involved in choroidal neovascularization (CNV) in AMD43–45. They regulate 
migration and recruitment of leukocytes and regulate the integrity of the blood-retinal barrier, particularly dur-
ing evolution of CNV and inciting irreversible tissue damage. In the present work we have shown that the pen-
tameric form of CRP does not confer a proinflammatory phenotype to ARPE-19 cells, while mCRP upregulated 
Figure 4. FH counteracts the proinflammatory effect of CRP on ARPE-19 cells. Chemotaxis assay was 
performed with Transwell chambers. PBMCs from healthy donors were seeded into the upper wells, while 
the lower chambers contained conditioned medium from ARPE-19 cells stimulated with the indicated 
concentrations of FH and/or CRP isoforms, and diluted 1:1 with RPMI. Results are expressed as fold-change vs. 
control ± SEM after 3 h incubation (n = 4). Statistical analysis was performed by ANOVA (*P < 0.05 vs. control, 
#P < 0.05 vs. mCRP).
Figure 5. Monomeric CRP, but not pCRP, binds tightly to FH. Various amounts of purified mCRP and pCRP 
were immobilized on a microtiter plate and serum (1;1,000 diluted) from AMD patients homozygous for the 
CFHH402 or CFHY402 variants was added. Bound FH was detected with a polyclonal anti-human FH antibody. 
Notice that mCRP (solid lines), but not pCRP (dashed lines), bound both FH variants in a dose-dependent 
manner. Further, mCRP bound tighter to the non-risk FH variant (filled circles, solid line) compared with the 
risk variant (filled squares, solid line) (n = 3). *P < 0.05 vs. pCRP, #P < 0.05 vs. mCRP-FHY402.
www.nature.com/scientificreports/
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IL8 and CCL2 gene expression and protein secretion in a dose-dependent manner. Notably, this effect was signif-
icant at concentrations above 2 μg/mL, which correspond to CRP plasma concentrations predicting risk of AMD 
in different studies10,12,42. (CRP levels higher than 10 μg/mL are usually attributed to other causes such as acute 
infection or inflammation). In line with previous studies in endothelial cells27, mCRP-induced cytokine produc-
tion was mediated by p38 MAPK and JNK, since their inhibition partially prevented mCRP effects. Furthermore, 
the increased secretion of IL-8 and CCL2 enhanced PBMC migration (Fig. 2). Our observations agree with pre-
vious studies showing mCRP-induced IL-8 and CCL2 upregulation in endothelial cells and neutrophils27,46–47. By 
contrast, our results are at odds with a previous report of increased IL-8 expression on ARPE-19 cells upon pCRP 
stimulation48. In this regard, we notice that Wang and colleagues used higher, supraphysiological concentrations 
of pCRP (up to 100 μg/mL), well above those associated with AMD risk.
In our hands, FH bound the monomeric CRP form rather than pCRP, as previously shown37,38,49. Further, we 
demonstrated that FH binding to mCRP counteracted its proinflammatory effects (Fig. 3). Notably, conditioned 
medium from cells treated with both FH and mCRP induced similar PBMC migration as that collected from 
untreated cells, and significantly lower than medium from mCRP-treated cells (Fig. 4). Of particular relevance 
when considering the etiology of AMD, we observed that the non-risk variant FHY402 bound more tightly to 
mCRP than the FHH402 risk variant (Fig. 5). Several previous studies have reported similar observations, but 
with the pentameric CRP form instead39,41,50,51. In this regard, it should be noted that immobilized pCRP in the 
absence of Ca2+ ions destabilizes the native fold and pentameric assembly, leading to dissociation38. Thus, it seems 
plausible that previous investigations on pCRP-FH interactions were actually reporting on mCRP-FH binding. 
In line with these findings, CRP levels in the RPE–choroid layer of individuals who are homozygous for the risk 
variant are higher than those of individuals homozygous for the non-risk associated form40, which could explain 
the chronic inflammation observed in AMD patients.
To explore the possible binding mode(s) of complement factor H to mCRP, we performed docking experi-
ments taking advantage of previously reported crystal structures of pCRP and FH fragments that include module 
SCR7. Six out of the ten top docking solutions identified by ZDOCK correspond to arrangements in which the 
Figure 6. FHY402 purified from sera of genotyped AMD patients counteracts mCRP-induced IL-8 and 
CCL2 upregulation in ARPE-19 cells more efficiently than the FHH402 risk variant. Cells were stimulated 
with FH purified from plasma of genotyped AMD patients and mCRP isoforms for 24 h. Concentrations of 
secreted IL-8 (A) and CCL2 (B) were measured by ELISA (n = 3). Statistical analysis was performed by ANOVA 
(*P < 0.05).
www.nature.com/scientificreports/
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aromatic side chains of Tyr402 and the nearby Tyr390/Tyr393 dock into a groove lined by CRP residues Trp162, Phe164 
and Phe180; a histidine side chain at position 402 could not fit this aromatic groove as good as the wild-type tyros-
ine. A representative solution is presented in Supplementary Figure 1B; it is particularly rewarding that additional 
interactions of surrounding residues would contribute to complex formation. Most notably, the carboxylate of 
Glu101 (CRP) could engage in simultaneous salt bridge formation with FH lysine residues at positions 388 and 
405, while the Arg188 and Glu395 side chains might form additional salt bridges. Although the W162/F164/F180 
crevice on the surface of the CRP molecule is fully accessible in the pentamer, these additional interactions are 
not possible in the pentameric form, as Glu101 faces the intermonomer interface to form a salt bridge with Lys201 
from a neighboring monomer. This feature might explain why FH preferentially engages mCRP but not pCRP in 
solution.
The impaired FH-mCRP interaction in individuals carrying the CFHH402 risk variant affected the ability of FH 
to prevent mCRP-mediated proinflammatory responses, as demonstrated using FH purified from sera of geno-
typed AMD patients. Remarkably, the non-risk variant of FH showed a significantly higher ability to counteract 
mCRP-induced IL-8 upregulation than the His402 form. Interestingly, in line with these findings, AMD patients 
carrying this risk variant of CFH had significantly higher levels of IL-8 and serum CRP than healthy subjects car-
rying the non-risk allele (Fig. 7). Further, the levels of these proteins were positively correlated in AMD patients 
homozygous for the risk CFH variant. Our results do conflict with a previous study showing that CRP levels and 
the CFHH402 polymorphism were independent risk factors for AMD52. We observed differences in hsCRP levels 
between subjects carrying the different CFH variants albeit in a smaller population. The corollary is that our 
results explain the previously reported higher risk of AMD within genetically susceptible individuals when CRP 
concentrations are high49. Indeed, higher levels of circulating CRP could derive in higher mCRP concentrations 
Figure 7. The circulating levels of IL-8 and CRP in AMD patients homozygous for the H402 variant of 
FH are higher than those of healthy individuals. Serum from healthy subjects homozygous for the non-risk 
(n = 30) and risk CFH alleles (n = 25), as well as from AMD patients homozygous for both alleles (n = 20 in 
both cases) were collected. Serum levels of IL-8 (A) and hsCRP (B) were determined by ELISA. Statistical 
analysis was performed by the Kruskal-Wallis test (*P < 0.05 vs. control).
www.nature.com/scientificreports/
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in microenvironments that favor dissociation (i.e. inflammatory or apoptotic conditions), which in the case of 
patients carrying the CFHH402 risk variant would further cause unchecked inflammation.
Recently, a specific pathophysiological role for mCRP in chronic inflammatory disorders such as cardiovas-
cular disease emerged22,28,29. In the context of AMD the presence of both CRP isoforms in ocular tissues has 
also been recently reported21. Notably, mCRP has been identified in AMD tissues along Bruch’s membrane and 
also in drusen, supporting the relevance of mCRP for the disease pathogenesis. Extrahepatic synthesis of CRP 
in different cell types has been reported53,54. However, we were unable to detect CRP gene expression in ARPE-
19 cells although we have not confirmed this in primary cultures. Alternatively, mCRP can be generated locally 
from dissociation of pCRP on the surface of necrotic or activated cells21,22,28. This process appears to depend on 
lysophosphatidylcholine exposure after phospholipase A2 activation as elegantly demonstrated by Thiele and 
colleagues in an in vivo animal model of acute cardiovascular inflammation24.
A previous work concluded that the association between the p.Tyr402His CFH polymorphism and AMD was 
due to a tighter association of the His402 variant with sulfated glycosaminoglycans (GAGs)55. In contrast, we 
demonstrate here a weaker binding of FHH402 to mCRP as a major factor underlying retinal degeneration. The two 
explanations are only apparently contradictory, however, and it is conceivable that both effects contribute to the 
etiology of AMD. In particular, it is evident that GAG-bound FH would not be able to complex mCRP generated 
in situ, as the two FH ligands share partially overlapping binding epitopes centered on residue 402. A mechanism 
that unifies currently available information on the role of mCRP-FH interactions for AMD progression is sche-
matically presented in Fig. 8.
The main limitation of our study is the use of a spontaneously arising RPE cell line, ARPE-19. Although 
ARPE-19 cells behave in many ways like primary RPE cultures this may not be always the case, and caution 
should be exercised when extrapolating our current results to an in vivo setting. Nevertheless, it must be stressed 
that ARPE-19 cells are commonly used for studying oxidative stress and cell signaling in AMD, as they show 
features of aged RPE. Therefore, the results reported herein appear valid as a first attempt to evaluate the role of 
mCRP on RPE cells in vitro.
In summary, our work shows that CRP is not only a risk marker but also is likely to contribute to the progres-
sion of AMD. Furthermore, our results highlight the importance of CRP quaternary structure on its function, as 
the monomer, but not the pentameric form, induced a proinflammatory response in a human RPE cell line. We 
also demonstrated that the proinflammatory effect of mCRP is not regulated by FH from subjects that carry the 
risk variant His402 of the complement regulator, due to an impaired interaction with mCRP. The ability of FH to 
bind mCRP and counteract the proinflammatory activity should be explored further by elucidating the structural 
basis of FH-mCRP complex formation.
Figure 8. A unified mechanism of mCRP-induced proinflammatory responses and the role of the CFH 
p.Tyr402His polymorphism. Generation of mCRP can occur spontaneously, but is accelerated in vivo under 
pathological conditions by bioactive lipids such as lysophosphatidylcholine (lysoPC) exposed on the surface of 
activated or damaged cells. mCRP is recognized by CD16 and/or other receptor(s) on the cell surface, leading to 
activation of MAPK pathways, and ultimately to enhanced expression of proinflammatory cytokines. Binding of 
FH to mCRP attenuates this inflammatory response, but the FHH402 variant is less effective in this regard, both 
because it binds tighter to glycosaminoglycans (GAG), but in particular due to its markedly lower affinity for 
mCRP. (Notice that FH domain SCR7, which contains residue 402 is colored differently in the two variants). 
The unchecked inflammatory response leads eventually to neovascularization, progression of AMD, and finally 
vision loss.
www.nature.com/scientificreports/
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Our current findings and those of other authors reinforce the importance of mCRP in inflammatory disorders 
and point to the CRP dissociation process and to mCRP-FH interactions as novel therapeutic targets. Along these 
lines, inhibition of pCRP dissociation with 1, 6-bis-PC, a compound that stabilizes CRP in a decameric form, 
abolished the proinflammatory effects of mCRP in vivo19. In a similar manner, therapeutic approaches aimed to 
enhance FH-mCRP binding could be developed to block mCRP proinflammatory activities, thus preventing the 
progression of AMD. Future research is warranted to confirm the contribution of mCRP to the disease etiology 
and progression and eventually to test the therapeutic potential of compounds that either prevent CRP dissocia-
tion or stimulate FH binding to mCRP in animal models.
Materials and Methods
Materials. High purity human pCRP and FH were purchased from Calbiochem. Kits for DNA or RNA 
isolation were from QIAGEN, and M-MuLV reverse transcriptase from Invitrogen. Antibiotics, amino acids 
and culture media were from PAA, and plates from Nunc. Transwell inserts were obtained from Corning. 
Chromatography resins were bought from GE Healthcare Life Sciences. Unless otherwise stated, all other rea-
gents, of the highest purity commercially available, were purchased from Sigma-Aldrich or GE Healthcare.
Patients. Patients with wet AMD (20 females and 20 males, mean age = 74) and controls (29 females and 26 
males, mean age = 71) were of Caucasian origin and were recruited at the Department of Ophthalmology of the 
Hospital Clínic of Barcelona. All patients and controls provided informed consent, and the research followed the 
tenets of the Declaration of Helsinki. The Hospital Clínic of Barcelona Institutional Review Board (IRB) approved 
this study according to local and national IRB guidelines. Blood was collected from patients and controls, and 
serum was prepared and stored at -70 °C until further analysis. Genomic DNA was extracted from peripheral 
blood using QIAmp DNA Blood Mini Kit. Exon 9 of the CFH gene (NM_000186), was amplified by polymerase 
chain reaction (PCR). PCR amplicons were purified with Illustra ExoStar 1-Step kit (GE Healthcare), bidirection-
ally sequenced using ABI BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and run on an 
automated ABI 3730XL DNA analyzer.
Generation and handling of mono- and pentameric CRP forms. Native human pCRP was stored 
in 10 mM Tris, 140 mM NaCl buffer (pH 8.0) containing 2 mM CaCl2 to prevent spontaneous dissociation of the 
native pentamer. mCRP was prepared by urea chelation from purified human CRP as previously described29. 
Briefly, pCRP at 1 mg/mL was chelated with 10 mM ethylene diaminetetraacetic (EDTA) and incubated in 8.0 M 
urea for 6 h at 37 °C. Urea was then removed via dialysis against low ionic strength TBS (10 mM Tris-HCl, 50 mM 
NaCl, pH 7.3). mCRP concentration was determined by the BCA protein assay. The filtered solution was stored 
at 4 °C. Because commercial CRP preparations can be contaminated with sodium azide or lipopolysaccharide 
(LPS)28, pCRP was also dialyzed into TBS before cell experiments.
FH purification from serum of genotyped individuals. For purification of FHY402 and FHH402 variants 
we followed the recently reported procedure, of Brandstätter and co-workers56, with slight modifications. Briefly, 
serum samples from patients homozygous for each of the FH variants (1 mL) were centrifuged at 15,000 rpm for 
2 min, supernatants were filtered (0.45 μm), and then Triton X-100 and tributyl phosphate were added to reach 
final concentrations of 1 and 0.325%, respectively. These solutions were incubated with stirring for 1 h at 4 °C, 
and then incubated for 45 min at 4 °C with 1 mL SP-Sepharose Fast Flow equilibrated in 20 mM sodium citrate, 
pH 6.0. The matrix was washed with citrate buffer containing 100 mM NaCl, and FH finally eluted with 200 mM 
NaCl. FH fractions were pooled, dialyzed against 25 mM Tris-HCl, pH 8.6 using a Centricon 50 K (Millipore), 
and incubated for 45 min at 4 °C with 1 mL Q-Sepharose Fast Flow equilibrated with the same buffer. FH was 
eluted with Tris-HCl buffer containing 250 mM NaCl. For cell experiments, fractions containing FH were dia-
lyzed against 50 mM sodium phosphate buffer, pH 7.5, and concentrated on a Centricon 50 K. The identity and 
purity of FH variants was verified by SDS-PAGE and Western blot using an anti-human FH (AbD Serotec) and by 
mass-spectrometry analysis of tryptic digests.
ARPE-19 cell culture. The spontaneously arising human RPE cell line, ARPE-19, was obtained from the 
American Type Culture Collection (ATCC). ARPE-19 cells were cultured in a 50:50 mixture of Dulbecco’s 
modified Eagle medium (DMEM) and Ham’s F12 supplemented with 10% fetal bovine serum (FBS), 2 mM 
L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1 mM sodium pyruvate in a humidified incuba-
tor at 37 °C in 5% CO2. Cells were passed every 4 to 5 days by trypsinization.
For cytokine stimulation cell suspensions of 1 × 105 cells/mL were seeded onto 24-well tissue culture plates 
and incubated overnight. Cells were then washed gently with phosphate-buffered saline (PBS) to remove cell 
debris, and starving fresh culture medium with 0.6% FBS was introduced for 18 h. Cells were then stimulated or 
not with human CRP isoforms (2–50 μg/mL) for 4–48 h. The responses to mCRP were also studied in the pres-
ence of mitogen activated protein kinase (MAPK) inhibitors. SB302580 (5 μM), U0126 (1 μM), and SP600125 
(20 μM) were used to inhibit p38 MAPK, MAPK kinase 1 and 2 (MEK1/2), and c-Jun N-terminal kinase (JNK), 
respectively. Additionally, experiments were also performed in the presence of antibodies capable of blocking 
Fcγ receptors (2.5 μg/mL of function-blocking anti-CD16 and/or anti-CD32 antibodies; Pharmingen). When 
indicated cells were treated 30 min before the addition of CRP isoforms with commercial human FH or with FH 
purified from sera of AMD-genotyped patients.
To explore CRP induction in ARPE-19 cells, cell suspensions of 1 × 105 cells/ml were seeded onto 24-well 
tissue culture plates and incubated overnight to allow the formation of a monolayer reaching 80% confluence. 
Cells were then stimulated with different combinations of proinflammatory cytokines: IL-17 (100 ng/mL), IL-1β 
(50 ng/mL), IL-6 (50 ng/mL), and/or TNF-α (50 ng/mL) for 24–48 h.
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Quantitative real-time PCR. One μg of RNA from cell lysates extracted using RNeasy isolation kit was 
reverse- transcribed with M-MuLV reverse transcriptase for 1 hour at 42 °C in a total volume of 25 μL. IL8, CCL2, 
and CRP mRNA levels were analyzed by real-time PCR. Assays on demand (Applied Biosystems) were used 
for IL-8 (Hs00174103m1), CCL2 (Hs00234140m1), and CRP (Hs04183452g1). Human GAPDH was used as 
endogenous control. Quantitative real-time PCR was performed on an ABI PRISM 7000 Detection System. The 
comparative CT method was used to determine the relative fold changes in gene expression.
Enzyme-linked immunosorbent assay (ELISA). Supernatants from CRP-stimulated cells were collected 
and centrifuged (1,000 × g for 15 minutes) to remove particulates, and stored at − 70 °C until further analysis. 
Protein concentrations of IL-8 and CCL2 were measured using human ELISA development kits (Ready Set Go 
eBiosciences). Each stimulation experiment was repeated five times. CRP levels in the cell supernatants were 
quantified using a commercial high-sensitivity ELISA kit specific for human CRP (hsCRP, IBL International 
GmbH; minimum detectable concentration 0.4 ng/mL) according to the manufacturer’s instructions. These 
experiments were performed in triplicate.
Isolation of human peripheral blood mononuclear cells (PBMC). Human PBMC were isolated from 
whole blood of healthy donors on a density gradient (Ficoll-Paque PLUS). PBMC were washed twice in RPMI 
1640 medium containing 2% FBS and resuspended at 2 × 106 cells/mL in PBMC starving medium (RPMI 1640 
containing 20 mM Hepes, 1% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin).
Chemotaxis assay. Chemotaxis assays were performed according to published methods. Conditioned 
media of ARPE-19 cells treated with different CRP isoforms diluted 1:2 with PBMC starving medium were used 
in the assay. Alternatively, PBMC starving medium supplemented with either 10 μg/mL of pCRP or mCRP was 
also used for chemotaxis experiments. Transwell inserts (6.5 mm in diameter, 5-μm pore) were placed in 24-well 
plates. One-hundred μL of a human PBMC suspension containing 2 × 105 cells and 100 μL of diluted conditioned 
medium or PBMC starving medium supplemented with CRP isoforms were added to the top and bottom com-
partments of each insert, respectively. PBMC were allowed to migrate for 3 h at 37 °C in a standard tissue culture 
incubator. After this period, the Transwell inserts were removed, cells were collected, and cells migrated to the 
bottom compartment were counted in a Neubauer chamber.
Binding of FH variants to CRP isoforms. Maxisorp microtiter plates were coated with CRP isoforms 
(0.5–10 μg/mL) overnight at 4 °C. After blocking, serum (1:1,000) from patients homozygous for the CFHH402 or 
CFHY402 variants was added. The plates were incubated for 1 h at 37 °C and washed twice. Biotinylated polyclonal 
anti-human FH (AssayPro human FH ELISA kit) was added, followed by the addition of streptavidin-peroxidase 
conjugate (AssayPro human FH ELISA kit). Chromogenic substrate was finally added, and absorbance was meas-
ured at 450 nm as indicated by the manufacturer.
Statistical analysis. Results were expressed as mean ± SEM. After testing for normal distribution and 
equality of variances with Levene F test, Student t, ANOVA or Kruskal Wallis tests as appropriate were used to 
determine statistical significance between treatments. A value of P < 0.05 was considered significant. All calcula-
tions were performed using SPSS Version 18.0 (SPSS, IBM).
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